Sanofi registers Phase 2 and 3 study of rilzabrutinib in iCVID
The study, first posted on ClinicalTrials.gov on November 6, 2026, plans to enroll 96 participants and has a planned start date of November 9, 2026. It evaluates efficacy, safety, and tolerability of rilzabrutinib in adults with inflammatory common variable immunodeficiency over four parts, with a planned primary completion date of May 10, 2035.
Primary source
ClinicalTrials.gov registry record, November 6, 2026
Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to Evaluate Efficacy, Safety, and Tolerability
Read the source: Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to Evaluate Efficacy, Safety, and Tolerability clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation